Name (Synonyms) | Correlation | |
---|---|---|
drug2466 | Rosuvastatin + BI 1323495 Wiki | 1.00 |
drug825 | Dabigatran etexilate + BI 1323495 Wiki | 1.00 |
drug824 | Dabigatran etexilate Wiki | 1.00 |
drug2464 | Rosuvastatin Wiki | 0.71 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0001626 | Abnormality of the cardiovascular system HPO | 0.19 |
There is one clinical trial.
The design included 152 patients with confirmed heart failure (HF) evaluated in two different periods of time: a baseline before the outbreak, and other during the outbreak of which 76 patients were randomized in each group. A care and follow-up guide was used as an instrument through a face-to-face survey (baseline group) and telemedicine (group outbreak). The primary outcome was the comparison of functional class modification observed in patients
Description: NYHA class modification in the last four weeks. Basal and follow-up measures: Basal on June 2020. Follow up: every three months and a year (June 2021). NYHA Scale: Minimum: 1 to maximum :4
Measure: NYHA class deterioration Time: 1 yearDescription: physiological parameter to worsening of shortness of breath perception, in last four weeks. Basal and follow-up measures: Basal on June 2020. Follow up: every three months and a year (June 2021).Dichotomic scale presence or absence
Measure: Dyspnea deterioration Time: 1 yearDescription: Physiological parameter to worsening of dyspnea that suddenly occurs to decubitus, in last four weeks. Basal and follow-up measures: Basal on June 2020. Follow up: every three months and a year (June 2021). Dichotomic scale presence or absence.
Measure: Paroxysmal nocturnal dyspnea deterioration Time: 1 yearDescription: Physiological parameter to worsening of quantification of swollen ankles in both pelvic limbs, in last four weeks. Basal and follow-up measures: Basal on June 2020. Follow up: every three months and a year (June 2021). Dichotomic scale presence or absence
Measure: Edema Time: 1 yearDescription: a perceived limitation on walking more 500 meters, in last four weeks. Basal and follow-up measures: Basal on June 2020. Follow up: every three months and a year (June 2021). Dichotomic scale presence or absence.
Measure: Daily activities In the last four weeks? Please, mention if you a perceived limitation on : Walking deterioration Time: 1 year